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Abstract
Background: There is high co-occurrence of substance use disorders (SUD) and mental health disorders. We aimed
to assess impact of substance use patterns and sociodemographic factors on mental health distress using the ten-
item Hopkins Symptom Checklist (SCL-10) over time.
Methods: Nested prospective cohort study of 707 participants with severe SUD across nine opioid-agonist-therapy
outpatient clinics and low-threshold municipality clinics in Norway, during 2017–2020. Descriptive statistics were
derived at baseline and reported by means and standard deviation (SD). A linear mixed model analysis was used to
assess the impact of substance use patterns and sociodemographic factors on SCL-10 sum score with beta
coefficients with 95% confidence intervals (CI).
Results: Mean (SD) SCL-10 score was 2.2 (0.8) at baseline with large variations across patients. We observed more
symptoms of mental health disorders among people with frequent use of benzodiazepines (beta 3.6, CI:2.4;4.8),
cannabis (1.3, CI:0.2;2.5), opioids (2.7, CI:1.1;4.2), and less symptoms among people using frequent stimulant use (−
2.7, CI:-4.1;-1.4) compared to no or less frequent use. Females (1.8, CI:0.7;3.0) and participants with debt worries (2.2,
CI:1.1;3.3) and unstable living conditions (1.7, CI:0.0;3.3) had also higher burden of mental health symptoms. There
were large individual variations in SCL-10 score from baseline to follow-up, but no consistent time trends indicating
change over time for the whole group. 65% of the cohort had a mean score > 1.85, the standard reference score.
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Conclusions: People with SUD have a considerable burden of mental health symptoms. We found no association
between substance use patterns and change in mental health symptoms over time. This could suggest that the
differences observed were indicating flattening of effects or self-medication to a larger degree than medication-
related decline in mental health. This call for better individualized mental health assessment and patient care.
Keywords: Substance use disorder, Substance abuse, Mental disorder, Psychological distress, Mental health
problems, Opioid substitution treatment, Opioid dependence
Background
Substance use disorders (SUD) contribute to 11.8
million deaths globally per year and 1.5% of the global
disease burden [1]. It is estimated that 2% of the world
population has a SUD, with some countries reporting a
prevalence of SUD greater than 5% [1]. More than half
of the people with a SUD will experience a mental health
disorder at some point during their lives [2, 3], yet it is
less clear whether mental health disorders develop
mostly as a consequence of substance use or vice versa
[4]. The co-occurrence of SUD and mental health disor-
ders may be attributed to shared genetic vulnerability
and pathophysiological processes possibly related to spe-
cific neurotransmitter systems [5, 6]. Even though most
research has been in relation to amphetamines, cannabis
and alcohol, comorbid mental health symptoms are
probably also the case for the more severe forms of SUD
like opioid dependence. However, less is known about
the prevalence, predictors and change over time of
mental health symptoms in these patient groups,
limiting optimal clinical care. It has been suggested that
these comorbidities often are under-recognized in clin-
ical settings [7, 8].
Among people with SUD in Europe, the most preva-
lent mental health disorders in epidemiological studies
are personality disorders (51%), mood disorders (35%),
attention-deficit hyperactivity disorder (30%) and anxiety
disorders (27%) [9–12]. Poor quality of life [13], concur-
rent drug use, including benzodiazepine misuse (e.g.
without prescription, higher frequency or dosage than
prescribed), is common and prevalent among SUD and
people enrolled in opioid agonist therapy (OAT) [14,
15]. Some research suggest that benzodiazepine misuse
are associated with other substance use, aggressive
behavior and worsening mental health symptoms and
disorders [16, 17]. Having a SUD, or a mental health dis-
order, is also likely to increase the risk for misuse of opi-
oids [18, 19]. Opioid dependence is the most severe
SUD, and of all illegal drugs, opioids represents the most
fatal risk factor, the highest disease burden and most ur-
gent demand for treatment [20, 21]. In addition, sub-
stance use patterns of cannabis and simulants especially
frequent use, are found to be associated with residual
cognitive impairment and poor mental health [22–24].
Attention to mental health symptoms could perhaps
better facilitate and optimize individualized mental health
care and SUD treatment to these marginalized and vulner-
able populations in low-threshold settings and OAT pro-
grams. It is therefore vital to identify and assess mental
health among the SUD population, as the co-occurrence
of SUD and mental health disorders are likely to be under-
served by current mental health systems [25, 26].
The aims of this prospective cohort study was to
examine prevalence and change over time of mental
health symptoms using the ten-item Hopkins Symptom
Checklist (SCL-10) among people with severe substance
use disorders (SUD) in Norway. In addition, the study
aimed to assess potential predictors of mental health
symptoms and change in symptom burden over time
from substance use patterns and injecting use while also
adjusting for level of education, living conditions, age
and gender.
Methods
Study design and setting
This study is a nested prospective cohort study linked to
the multicenter INTRO-HCV study [27]. The data was
collected from May 2017 until July 2020 as part of an an-
nual health assessment among people with SUD in nine
OAT outpatient clinics in Bergen and Stavanger and two
low-threshold municipality clinics in Bergen. The OAT
clinics have implemented an integrated treatment and
care model where patients are followed-up on a near daily
basis by general and specialized nurses, psychologists and
physicians who are under specialization- or specialized in
addiction medicine. Buprenorphine-based and methadone
are the two main OAT medications [28]. People with
SUD in the municipality clinics are followed-up by social
workers, general nurses and physicians specialized in fam-
ily medicine. The INTRO-HCV study have employed
trained research nurses who collected and completed the
structured patient interviews, which were recorded in a
health register using an electronic data collection software
(CheckWare).
Study sample
The study sample was comprised of two groups of pa-
tients; individuals diagnosed with opioid dependence
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(F11.2) according to World Health Organization’s Inter-
national Classification of Diseases version 10 (ICD-10)
[29], which were enrolled in OAT during the study
period and accounted for 83% of the total study sample
at baseline. The other participants were recruited from
low-threshold municipality clinics among people who in-
ject drugs. For the purpose of this paper, a SUD was de-
fined as harmful use of, or dependency of a substance,
and a severe SUD was defined as dependency of one or
more substances. All included individuals were 18 years
or older at time of inclusion and signed a written in-
formed consent to partake in the study. Altogether 1042
SCL-10 measurements were included from 707 partici-
pants. Of the 707 participants with SCL-10 measures at
baseline and 268 (38%) were included in a follow-up as-
sessment with 67 (10%) having at least three annual
measuring points. The mean time between SCL-10 mea-
surements was 364 days (standard deviation (SD) 133).
Table 1 shows details on clinical and sociodemographic
characteristics of the study sample.
Assessment
Measuring mental health status: Hopkins symptom
check list (SCL-10).
Table 1 Basic characteristics of study sample
Participants, n (%) Baseline (n = 707) Follow-up (n = 268)
Gender
Male 500 (71) 208 (78)
Female 207 (29) 60 (22)
Age, n (%)
18–29 83 (12) 25 (9)
30–39 203 (29) 71 (26)
40–49 217 (31) 87 (32)
50–59 161 (23) 71 (26)
≥ 60 43 (6) 14 (5)
Mean (SD) 43 (11) 45 (10)
Highest education completed, n (%)
Not completed lower secondary school 41 (6) 15 (6)
Completed lower secondary school (9 years) 309 (44) 128 (48)
Completed upper secondary school (12 years) 285 (40) 99 (37)
Completed under or postgraduate studies (≥ 12 years) 72 (10) 26 (10)
Current living conditions, n (%)
Stable (owned, rented or incarcerated) 619 (88) 242 (90)
Unstable (homeless, with family/friends) 88 (12) 26 (10)
Worrying debt situation 292 (41) 116 (43)
Participants enrolled in OAT, n (%) 590 (83) 248 (93)
OAT medications of those; n (%)
- Methadone 224 (38) 110 (44)
- Buprenorphine-based 357 (61) 134 (54)
OAT treatment ratio*, mean (SD) 0.9 (0.4) 0.9 (0.3)
Injecting and frequent substance use past 12months, n (%)
Injected at least once 352 (54) 142 (53)
Alcohol 165 (25) 67 (25)
Cannabis 329 (50) 145 (55)
Stimulants (amphetamine/methamphetamine/cocaine) 183 (28) 73 (27)
Opioids (other than OAT) 103 (16) 29 (11)
Benzodiazepines 248 (38) 104 (39)
SD = standard deviation, OAT = Opioid agonist therapy,
*OAT ratio = ratio between daily OAT medication dose divided by expected mean daily dose; for buprenorphine 18 mg, buprenorphine-naloxone 18/4.5 mg or
methadone 90 mg
Frequent substance use was defined as using substance at least weekly during the past 12months
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The SCL-10 is a structured and self-administrated
questionnaire, designed to measure symptoms of mental
health disorders and psychological distress, and is widely
used for both clinical and epidemiological purposes [30–
32]. The SCL-10 involves ten items (suddenly scared for
no reason, feeling fearful, faintness, dizziness or weak-
ness, feeling tense, blaming yourself, difficulties falling
asleep, feeling of worthlessness, feeling blue, feeling
hopeless, and feeling everything is an effort), which are
each scored on four dimensions from not bothered at all
(item score = 1) to extremely bothered (item score = 4).
Scores were summed and divided by the number of
items answered to derive the mean item score. Mean
scores vary between one and four, where the latter as-
sumes extremely bothered. SCL-10 mean item scores
were used for descriptive analyses while SCL-10 sum
scores were used in linear mixed model (LMM) analyses.
Furthermore, the mean item scores were calculated by
gender, age, level of education, and living conditions at
baseline. By introducing a cut-off point one can interpret
the proportion of the respondents with symptoms of
mental health disorders. A mean score of 1.85 for SCL-
10 has been recommended as a threshold for indicating
substantial mental health distress [31].
Study variables; baseline, OAT, clinical and
sociodemographic factors
Baseline was defined as the time when the first SCL-10
measure was completed upon the participant’s first an-
nual health assessment. Subsequent SCL-10 measures at
the next health assessment(s) were listed chronologically
and included as follow-up. Being on OAT was defined
as receiving either buprenorphine-based or methadone
medication at baseline. Moreover, the OAT ratio,
which corresponds to the received dose of OAT
medication per day divided by expected mean dose
(buprenorphine 18 mg or methadone 90 mg) according
to World Health Organization [33], was calculated
per OAT patient. For the clinical factors we defined
injecting substances as having injected any substance
during the last 12 months, and frequent substance use
as using a substance more than once weekly during
the last 12 months according to the subcategories of
alcohol, cannabis, stimulants (amphetamine/metham-
phetamine/cocaine), opioids (non-OAT), and benzodi-
azepines (including z-hypnotics).
Statistical analysis
All descriptive analyses were performed using STATA/
SE 16.0. Expectation-maximization (EM) imputation and
LMM analyses were performed in IBM SPSS version
26.0. Statistical significance was set at the p < 0.05 level.
Missing values of SCL-10, clinical and sociodemographic
variables, which included substance use, injecting sub-
stance use, educational level, worrying debt situation,
and living conditions were assumed to be missing at ran-
dom when performing EM imputation. There were miss-
ing values for 3.4% of these values, which were
subsequently replaced with the estimated values by EM
imputation according to Enders (2010) [34].
A LMM analyses were used to evaluate the impact of
clinical and sociodemographic factors on the SCL-10
sum score. Time was defined as years from baseline
Firstly, we ran a LMM analysis where each defined pre-
dictor variable was set against time, to assess whether
the predictor variable changed over time. There were no
clinical significant changes in these variables when ana-
lyzed separately as outcome variables – with the time
variable being the exposure variable (data not shown).
Thus, these predictor variables were included as con-
stant and time-independent variables in further analyses.
Secondly, a new LMM analysis was generated where
these time-independent predictor variables were set
against the SCL-10 sum score being the outcome vari-
able. In addition, we added a time interactional to each
predictor variable to investigate if time impacted
changes of SCL-10 given each predictor. The predictor
variables, on the baseline level and change in SCL-10
sum score, represented as main effects and interaction
effects with time. The model was a random intercept
fixed slope model with restricted maximum likelihood
set as the estimator. This model uses all available data in
the outcome variable.
Results
Basic characteristics of the study sample
Seventy-one percent of the study sample were male,
mean (SD) age of 43 (11) at baseline and 45 (10) at
follow-up for the whole cohort (Table 1). Approximately
40% had completed upper secondary school. Most par-
ticipants (88%) had a stable living condition and 41%
had a concerning debt situation. Eighty-two percent of
the study sample was in OAT, of which 61 and 38% re-
ceived buprenorphine-based medication and methadone,
respectively. Over half had injected substances at least
once during the last year, while 71% reported frequent
substance use; most prevalent substances being cannabis
(50%) and benzodiazepines (38%).
SCL-10 scores at baseline and follow-up
The mean (SD) of the SCL-10 item scores was 2.2 (0.8)
(Table 2) at baseline. The distribution was sharply-
peaked (kurtosis: 2.2) and slightly right-skewed (skew-
ness: 0.4). The lowest mean (SD) item score (SD) was
found for suddenly scared for no reason at 1.9 (1.1) and
the highest score 2.5 (1.2) for difficulty in falling asleep
(Fig. 1 and Additional File 1). Overall, females reported
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mean (SD) SCL-10 item score of 2.3 (0.8) and men 2.2
(0.8) [31].. People with unstable living conditions re-
ported more symptoms of mental disorders than people
with stable living conditions. Among OAT treatment,
people on methadone reported mean (SD) SCL-10 of 2.3
(0.7) and buprenorphine-based medications at 2.2 (0.8).
SCL-10 = Symptoms checklist 10; ten items scale for
measuring mental health status/psychological distress.
The figure displays the proportion of patients re-
sponses on the ten item scale, from not bothered at all
(item score = 1) to extremely bothered (item score = 4).
We found vast individual dissimilarities in subjective
mental health symptoms at baseline (Additional File 2);
minimum and maximum mean SCL-10 item score was
one and four, respectively. Thirty-three participants
(4.7%) reported a mean of one; meaning not bothered at
all on any items, while three participants (0.4%) were ex-
tremely bothered on all items. Sixty-five percent of the
cohort reported a mean SCL-10 above the 1.85 cut-off
point, which is recommended as a predictor of mental
disorder [31] as shown in the Pen’s Parade below.
Pen’s Parade: SCL-10 = Symptoms checklist 10; ten
items scale for measuring mental health status/psycho-
logical distress.
The figure displays distribution in SCL-10 mean values
at baseline (n = 707) and follow up (n = 268), represented
by fixed black line and vertical grey lines. The dotted
lines represent the mean reported SCL-10 score of the
Norwegian reference population (1.36) and standard ref-
erence of 1.85 indicating one or more mental disorders
above this cut-off, respectively. Source: Strand BH, Dal-
gard OS, Tambs K, Rognerud M: Measuring the mental
health status of the Norwegian population: a comparison
of the instruments SCL-25, SCL-10, SCL-5 and MHI-5
(SF-36). Nordic journal of psychiatry 2003 [31].
Altogether 268 (38%) of the 707 participants at base-
line had SCL-10 measures at two data points. As shown
in Fig. 2, individual SCL-10 score at first follow-up are
indicated with grey points and individual changes from
baseline with vertical lines. Sharp changes go in both
positive and negative directions and appear considerable
for some.
Impact of substance use patterns, clinical and
sociodemographic factors on baseline level and change in
SCL-10 sum score
Using a LMM analysis, we found higher SCL-10 sum
scores at baseline for females (SCL-10 sum score: 1.8,
95% confidence interval (CI): 0.7 to 3.0) compared to
men, people with unstable living conditions (1.7, CI: 0.0
to 3.3) and having a worrying debt (2.2, CI: 1.1 to 3.3)
compared to people with stable living conditions and
non-worrying debt, respectively. For substances, fre-
quent use of cannabis (1.3, CI: 0.2 to 2.5), other opioids
(2.7, CI: 1.1 to 4.2) and benzodiazepines (3.6, CI: 2.4 to
4.8) were associated with higher SCL-10 scores at base-
line compared to people with no or non-frequent use of
these substances (Table 3). On the other hand, frequent
use of stimulants was associated with lower SCL-10 sum
score at baseline (− 2.7, CI: − 4.1 to − 1.4) compared with
people with no or less frequent use. There were no sig-
nificant time interactions between any of the substance
use patterns and changes in the SCL-10 sum score, nor
were there any significant time interactions with socio-
demographic characteristics.
Discussion
In this study, we found that 65% of people with SUD
have symptoms of mental health disorders and psycho-
logical distress. Mental health symptoms were particu-
larly prevalent among females, people with frequent use
of cannabis, non-OAT opioids, and benzodiazepines
compared to men and people with no or less frequent
use of these substances. Interestingly, there were no
clear associations between substance use patterns and
Table 2 Baseline SCL-10 mean item scores and standard
deviation (SD) by gender, age and sociodemographic factors












Highest level of education, n 705
Not completed lower secondary school 2.46 0.78
Completed lower secondary school (9 years) 2.24 0.78
Completed upper secondary school (12 years) 2.14 0.72
Completed undergraduate studies (≤ 15 years) 2.28 0.77
Completed postgraduate studies (≥ 15 years) 2.16 0.66
Current living conditions, n 705
Stable (owned, rented or incarcerated) 2.19 0.74
Unstable (homeless, with family/friends) 2.40 0.84
Enrolled in OAT and by medication, n 583
Methadone 2.28 0.71
Buprenorphine 2.15 0.77
SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health
status/psychological distress, SD =standard deviation, OAT = opioid
agonist therapy
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Fig. 1 Proportion of SCL-10 item scores at baseline. SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health status/
psychological distress. The figure displays the proportion of patients responses on the ten item scale, from not bothered at all (item score= 1) to
extremely bothered (item score = 4)
Fig. 2 Pen’s Parade: Distribution of mean SCL-10 item scores at baseline and follow-up. Pen’s Parade: SCL-10 = Symptoms checklist 10; ten items
scale for measuring mental health status/psychological distress. The figure displays distribution in SCL-10 mean values at baseline (n=707) and
follow up (n=268), represented by fixed black line and vertical grey lines. The dotted lines represent the mean reported SCL-10 score of the
Norwegian reference population (1.36) and standard reference of 1.85 indicating one or more mental disorders above this cut-off, respectively.
Source: Strand BH, Dalgard OS, Tambs K, Rognerud M: Measuring the mental health status of the Norwegian population: a comparison of the
instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nordic journal of psychiatry 2003 [31]
Aas et al. Substance Abuse Treatment, Prevention, and Policy           (2021) 16:20 Page 6 of 10
change in mental health symptoms over time. This could
suggest that the differences observed were indicating
self-medication to larger degree than medication-related
decline in mental health.
People with SUD are a heterogeneous population; fif-
teen and 35 % reported lower mean SCL-10 item scores
compared to the general population and the standard
reference score for symptoms of mental health disorders,
respectively. Despite vast intra-individual variations in
SCL-10 score from baseline to first follow-up, going in
both directions, there were no time trends indicating
change over time for the total study sample. This indi-
cates that mental health disorders and psychological dis-
tress persist over time for this group and we are not able
to explain the huge shift, positive and negative, in mental
status of many individuals.
The mean SCL-10 for our cohort was 2.2, which is
considerable lower compared to the general Norwegian
population at 1.4, estimated to be around 11% of the
population [31]. Around two-thirds of the total study
sample reported symptoms of mental health disorders.
This was somewhat higher symptom burden compared
to cohort among people with SUD in Sweden [35], how-
ever, lower compared to a study among people entering
SUD treatment in Norway, which found that over 80%
had a level of mental distress above the 1.85 cut-off for
SCL-10 at admission [36]. This could reflect that initiat-
ing SUD treatment, often combined with strict detoxifi-
cation, is a very stressful event, whereas most of the
patients included in our cohort were long-term OAT pa-
tients with a mean treatment time of almost eight years
[13]. Correspondingly, follow-up studies have shown
that there may be a significant reduction in SCL-10
symptoms when these individuals are discharged from
inpatient treatment, however, presence of mental health
disorders and severity of substance use seem to be inde-
pendent predictors of considerable symptoms of mental
health disorders in the long-term [37, 38]. We found
that mental health symptoms at baseline were associated
with a worrying debt situation, unstable living conditions
and a frequent use of some of the substances. Severe
debt has been found to correlate with poor mental
health in a systematic review summarizing a number of
studies [39]. There are also several studies suggesting a
strong relationships between substance use and psycho-
logical distress, despite hardship to establish exact caus-
ality [40–42]. In the above study among people entering
SUD treatment, severity of substance use, although
stratified into alcohol use, illicit drug use and number of
substances used– but not the actual substances used;
was the most significant predictor of symptoms of men-
tal health disorders [36]. However, again the question
Table 3 Linear mixed model of SCL-10 adjusted for clinical and sociodemographic factors
Fixed effects
Baseline Change per year
n = 707 Estimate (95% CI) Slope (95% CI)
Factor impact* on SCL-10 sum score at baseline and changes per year from baseline
SCL-10 sum score 18.1 (15.9 to 20.2) 0.6 (−1.6 to 2.9)
Female 1.8 (0.7 to 3.0) 0.4 (−0.9 to 1.8)
Age per 10 years 0.0 (−0.1 to 0.0) 0.0 (0.0 to 0.1)
Clinical factors
Injecting substance use
Injecting at least once last 12 months 0.6 (−0.7 to 1.8) −0.3 (−1.6 to 1.0)
Frequent use of substances
Alcohol 0.7 (−0.6 to 1.9) 0.1 (−1.2 to 1.4)
Cannabis 1.3 (0.2 to 2.5) 0.3 (−0.9 to 1.4)
Stimulants (amphetamines/ cocaine) −2.7 (−4.1 to − 1.4) − 0.2 (−1.6 to 1.3)
Opioids (other than opioid dispensed on OAT) 2.7 (1.1 to 4.2) −2.6 (− 4.7 to − 0.4)
Benzodiazepines 3.6 (2.4 to 4.8) − 0.4 (− 1.7 to 0.8)
Sociodemographic factors
Level of education −0.1 (− 0.7 to 0.6) −0.6 (− 1.3 to 0.1)
Unstable living conditions 1.7 (0.0 to 3.3) 1.1 (−1.0 to 3.3)
Worrying debt situation 2.2 (1.1 to 3.3) 0.4 (−0.7 to 1.6)
SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health status/psychological distress, CI = confidence interval
*Age per 10 years (centered according to mean age 43 years), level of education was coded 0–4 with 4 as the highest educational level, living conditions; unstable
situation homeless or non-permanent residence, worrying debt situation: including any legal or illegal fees and debt, injecting substance use: during
last 12months
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arises whether these symptoms are the direct result of
the substance use or symptoms of mental distress pre-
senting upon treatment admission [36].
In our study, use of cannabis, non-OAT opioids and
benzodiazepines were co-occurring with mental health
distress at baseline, while the opposite was seen for stim-
ulants. There were no changes in time trends between
use of substances and mental health symptoms. One hy-
pothesis for these findings could be that the associations
at baseline might be due to reverse causality, i.e. that
participants with substantial mental health symptoms
use substances to self-medicate symptoms [43]. It is also
possible that there is a “flattening effect” and that poten-
tial negative impact of substances are more substantial
at an earlier phase and that the change in later phases
are less pronounced. Other research indicate that high
doses of benzodiazepines reduce social functioning, and
that it may also increase psychological distress and
worsen mental health [16, 44], and misuse of benzodiaz-
epines is seen among both SUD and psychiatric popula-
tions alike [45]. Similarly, the use of stimulants, in
particular methamphetamine, has been associated with
poor mental health outcomes [23]. Self-medication of at-
tention deficit hyperactivity disorder (ADHD) with stim-
ulants could be one explanation for these findings. Yet
one study found that high ADHD symptom burden was
associated with higher mental distress and use of simu-
lants among OAT patients [46]. It is estimated that up
to a third of patients in OAT have ADHD and previ-
ously we have found that coverage of central acting
stimulants in this patient group is very low [12, 47, 48].
An alternative explanation could be that stimulants have
a direct positive impact on mental health symptoms
among these patients. However, the time trend analyses
does not support these hypotheses.
Although prevalence of mental disorders and SUD co-
morbidity has been found to vary among European
countries; research consistently shows a high total preva-
lence of around 50%, with depression, anxiety disorders
and personality disorders being the most frequent [9].
However, some facility based studies indicate an even
higher comorbidity prevalence as people with severe
symptoms are more likely to seek support; 70% for
personality disorders [3] and a lifetime substance-
independent mental disorder was found in nine out of
ten patients enrolled in treatment facilities [49]. Comor-
bid mental health disorders and SUD have been found
to be associated with poor treatment outcomes and
show a higher psychopathological severity compared to
people with a single disorder [50–52], and this under-
lies the importance of assessing mental health status
in clinical settings among people with SUD. We en-
dorse that evaluation of mental health and linkage to
mental health care services should be included in
OAT programs and low-threshold SUD clinics; be
gender-sensitive and follow and integrated treatment
approach, which have been found superior compared
to separate treatment plans [53–55].
The major strength of this study is the relatively large
sample size of a “hard-to-reach” population of people
with SUD as well as a cohort design. However, there are
some limitations. Firstly, only a minority contributed to
the prospective analyses (268/707). To reduce the poten-
tial for selection bias between the sub-group with
follow-up SCL-10 measurements presented in Fig. 2 and
the baseline cohort, we conducted an inverse probability
weighted analysis. Our study sample is also mainly rele-
vant for people with opioid dependence being enrolled
in OAT treatment as most were in this group. Thus, our
research might not be generalized to other groups with
SUD. Moreover, both in the OAT and low-threshold
SUD clinics, patient- and system delays contributed to
non-accurate annual health assessments, which could in
turn affect both answers and results. Thirdly, the SCL-
10 has limitations. It is not a diagnostic tool for mental
health disorders and is no replacement for clinical inter-
views and more comprehensive psychiatric instruments
among people with SUD. Literature also suggests that
the SCL-10 predicts depression and anxiety better than
other diagnosis, and that some 50–60% of the patients
identified with symptoms of mental disorders qualify for
at least one or more mental disorders when assessed
clinically [31, 56, 57].
Conclusion
People with SUD have considerable symptoms of mental
health disorders and psychological distress. However,
this is a diverse and dynamic population with extreme
individual variations. Around one-third have few symp-
toms of mental health disorders. This emphasizes the
importance of consideration and evaluation of symptoms
of mental health disorders and psychological distress in
both OAT and low-threshold SUD clinics to further im-
prove personalized patient care. Mental health problems
were particularly observed among females, people with
frequent use of cannabis, opioids, and benzodiazepines,
and less among people using amphetamines. Time trend
analyses could suggest that the differences observed in-
dicates self-medication or a flattening effect rather than
medication-related decline in mental health. Studies with
long term follow-up or experimental design is needed to
confirm these potential effects better.
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